{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:34:45Z","timestamp":1791063285546,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> The present study aimed to compare the clinicopathological features of patients with seronegative immune-mediated necrotizing myopathy (IMNM) and those positive for anti-signal recognition particle (SRP) or anti-3-hydroxy-3-methylglutarylcoenzyme-a reductase (HMGCR) antibodies.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We retrospectively analyzed the data of patients with IMNM treated in the Neurology Department of Tongji Hospital from January 1, 2013, to December 31, 2019.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among the 117 patients with IMNM, 30.8% (36\/117) were positive for anti-SRP antibodies, 6.0% (7\/117) were positive for anti-HMGCR antibodies, and 13.7% (16\/117) were seronegative. Myalgia at presentation (62.5 vs. 23.3%, <jats:italic>p<\/jats:italic> = 0.0114) was more commonly observed in patients with seronegative IMNM than in those with seropositive IMNM. Subclinical cardiac involvement was more frequently detected in seronegative IMNM than in seropositive IMNM (6\/13 vs. 5\/33, <jats:italic>p<\/jats:italic> = 0.0509, echocardiogram; 7\/7 vs. 12\/24, <jats:italic>p<\/jats:italic> = 0.0261, cardiac MRI). Deposition of membrane attack complex (MAC) on the sarcolemma of myofibers in biopsied muscle was less commonly observed in patients with seronegative IMNM than in patients with seropositive IMNM (16.7 vs. 68.2%, <jats:italic>p<\/jats:italic> = 0.0104). The rate of marked improvement following immunotherapy tended to be higher in patients with seronegative IMNM than in those with seropositive IMNM (87.5 vs. 61%, <jats:italic>p<\/jats:italic> = 0.0641).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Patients with seronegative IMNM more frequently present with myalgia at onset, exhibit more subclinical cardiac involvement and uncommon MAC deposition on myofibers, and experience better outcomes than those with seropositive IMNM.<\/jats:p>","DOI":"10.3389\/fneur.2021.670784","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T04:57:56Z","timestamp":1625461076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China"],"prefix":"10.3389","volume":"12","author":[{"given":"Xue","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqiong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.semarthrit.2019.04.002","article-title":"Immune-mediated necrotising myopathy: A critical review of current concepts","volume":"49","author":"Day","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","article-title":"Autoimmune myopathies: updates on evaluation and treatment","volume":"15","author":"McGrath","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"Jama Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscular Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscular Disorders: NMD"},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11926-018-0763-z","article-title":"Potential pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in immune-mediated necrotizing myopathies","volume":"20","author":"Ladislau","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy","author":"Lim","year":"2019","journal-title":"Neurol-Neuroimmunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"B10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle & Nerve"},{"key":"B11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscular Disord"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain: a Journal of Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1212\/WNL.50.3.764","article-title":"Paraneoplastic necrotizing myopathy: clinical and pathological features","volume":"50","author":"Levin","year":"1998","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol-Neuroimmunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"Jama Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JND-140054","article-title":"Diagnostic utility of auto-antibodies in inflammatory muscle diseases","volume":"2","author":"Allenbach","year":"2015","journal-title":"Journal of Neuromuscular Diseases"},{"key":"B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"B20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.autrev.2018.10.004","article-title":"Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays","volume":"18","author":"Darnoiseaux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscular Disorders: NMD"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3389\/fneur.2018.01028","article-title":"Severe recurrent necrotizing myopathy in pregnancy: a case report","volume":"9","author":"Li","year":"2018","journal-title":"Front Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2340\/16501977-0235","article-title":"Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy","volume":"40","author":"Paternostro-Sluga","year":"2008","journal-title":"J Rehabil Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/annrheumdis-2016-210198","article-title":"Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity","author":"Pinal-Fernandez","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosur Ps"},{"key":"B26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1532-429X-17-S1-P277","article-title":"Early detection of myocardial involvement in idiopathic inflammatory myopathies assessed by cardiac magnetic resonance imaging","volume":"132","author":"Buckert","year":"2015","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1871528113666140526162640","article-title":"Cardiac and muscular involvement in idiopathic inflammatory myopathies: noninvasive diagnostic assessment and the role of cardiovascular and skeletal magnetic resonance imaging","volume":"13","author":"Mavrogeni","year":"2014","journal-title":"Inflamm Allergy Drug Targets"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol-Neuroimmunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jocn.2018.08.010","article-title":"Statin-naive anti-HMGCR antibody-mediated necrotizing myopathy in China","volume":"57","author":"Jiao","year":"2018","journal-title":"J Clin Neurosci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04973-0","article-title":"Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies","author":"Hamaguchi","year":"2020","journal-title":"Clinical Rheumatology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.670784\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T04:57:59Z","timestamp":1625461079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.670784\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":33,"alternative-id":["10.3389\/fneur.2021.670784"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.670784","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"670784"}}